Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis

Conus, Sébastien; Straumann, Alex; Simon, Hans-Uwe (2009). Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis. Journal of allergy and clinical immunology, 123(1), 269; author reply 269-70. St. Louis, Mo.: Mosby 10.1016/j.jaci.2008.09.031

Full text not available from this repository. (Request a copy)

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
UniBE Contributor:	Simon, Hans-Uwe
ISSN:	0091-6749
Publisher:	Mosby
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:10
Last Modified:	05 Dec 2022 14:21
Publisher DOI:	10.1016/j.jaci.2008.09.031
PubMed ID:	18951621
Web of Science ID:	000262793900049
URI:	https://boris.unibe.ch/id/eprint/30720 (FactScience: 194998)